For example, NRF2 activation promotes lung cancer metastasis [92] and associates with poor clinical outcomes [93]; enhanced NRF2 expression increases risk of high tumor mutation burden in the genome overall in acute myeloid leukemia [94] and correlates with poor prognosis in colorectal cancer patients [95]; upregulation of NRF2 expression induced by Keap1 downregulation contributes to poor prognosis and Axitinib resistance in RCC [96]; and the NRF2/HO-1 axis can be a prognostic factor in ccRCC [97]. Here, KEAP1 is linked to lung cancer.